Thus, while in several types of human cancer stathmin overexpression is typically found in advanced/metastatic disease (reviewed in Belletti & Baldassarre, 2011) and in mice is not required for the onset of sarcoma, skin and bladder carcinomas (D'Andrea et al, 2012), our and others' data pointed to type II HG-EOC as a neoplasia in which stathmin expression is required at early stages of tumour onset, downstream of p53 mutation. Here, TP53 is linked to neoplasm.